Human gene therapy: A scientometric analysis

Zhou, Wuyuan; Wang, Xiang

doi:10.1016/j.biopha.2021.111510

Cited by 15 publications

(4 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most of the publications were related to AAV. AAV vector discovery saves gene therapy from failed clinical trials, and breakthroughs in gene therapy depend on more advanced science and technologies [ 37 ].…”

Section: Discussionmentioning

confidence: 99%

Progress and prospects of gene therapy in ophthalmology from 2000 to 2022: A bibliometric analysis

Tan

Wang

et al. 2023

Heliyon

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Progress and prospects of gene therapy in ophthalmology from 2000 to 2022: A bibliometric analysis

Tan

Wang

et al. 2023

Heliyon

View full text Add to dashboard Cite

“…The earliest clinical studies on gene therapy started with the first human gene therapy trial conducted in 1989 in patients with advanced melanoma [ 133 ]. Out of the approximate 2597 clinical trials on gene therapy conducted worldwide by 2017, more than 65% were designed for cancer management.…”

Section: Challenges and Future Directionsmentioning

confidence: 99%

Oncolytic virus-based suicide gene therapy for cancer treatment: a perspective of the clinical trials conducted at Henry Ford Health

et al. 2023

View full text Add to dashboard Cite

Gene therapy manipulates or modifies a gene that provides a new cellular function to treat or correct a pathological condition, such as cancer. The approach of using gene manipulation to modify patient’s cells to improve cancer therapy and potentially find a cure is gaining popularity. Currently, there are 12 gene therapy products approved by US-FDA, EMA and CFDA for cancer management, these include Rexin-G, Gendicine, Oncorine, Provange among other. The Radiation Biology Research group at Henry Ford Health has been actively developing gene therapy approaches for improving clinical outcome in cancer patients. The team was the first to test a replication-competent oncolytic virus armed with a therapeutic gene in humans, to combine this approach with radiation in humans, and to image replication-competent adenoviral gene expression/activity in humans. The adenoviral gene therapy products developed at Henry Ford Health have been evaluated in more than 6 preclinical studies and evaluated in 9 investigator initiated clinical trials treating more than100 patients. Two phase I clinical trials are currently following patients long term and a phase I trial for recurrent glioma was initiated in November 2022. This systematic review provides an overview of gene therapy approaches and products employed for treating cancer patients including the products developed at Henry Ford Health.

show abstract

“…Since the rise of gene therapy as a potential treatment method for various illnesses in the 1990s, the eld has been consistently researched 5 . The precision of the ability to modify speci c genes o ers great potential.…”

Section: Introductionmentioning

confidence: 99%

“…However, due to obstacles such as high cost, ethical concerns, and di culty translating into clinical applications 5 , there is still much to uncover.…”

Section: Introductionmentioning

confidence: 99%

Novel Methods for Inducing Cardiac Tissue Regeneration Following Ischemic Injury

Chu¹,

Jeyakumar²,

Koo³

et al. 2022

bptjm

View full text Add to dashboard Cite

Cardiac disease continues to be among the most prevalent causes of death worldwide. Presently, surgeries such as angioplasties, stents, and bypasses pose many risks. To improve outcomes in treating ischemia, researchers have been pursuing minimally invasive, biocompatible treatments such as gene therapies. Gene therapies are treatments that enhance or suppress target genes to alleviate illness. There are various applications for gene therapies, including, but not limited to, the treatment of cancers, diabetes, and heart disease. Gene and stem cell therapies can regenerate cardiac tissue that is damaged due to ischemia. Furthermore, gene therapies intended to evade the immune system may decrease infection risks due to the new tissue being better accepted by the body as it is created from patients’ own cells. While DNA treatments show poor results in treating cardiac illness, stem cells, such as mesenchymal stem cells and induced pluripotent cells, can differentiate into cardiomyocytes, and mRNA can be modified to express angiogenesis growth factors around the affected tissue. Although further research is needed to adapt these techniques for safe clinical use, they show potential for inducing cardiac tissue regeneration in ischemic injury. This paper conducts a review of the emerging techniques and evaluates gene therapy as a potential treatment for ischemic injury.

show abstract

Human gene therapy: A scientometric analysis

Cited by 15 publications

References 38 publications

Progress and prospects of gene therapy in ophthalmology from 2000 to 2022: A bibliometric analysis

Progress and prospects of gene therapy in ophthalmology from 2000 to 2022: A bibliometric analysis

Oncolytic virus-based suicide gene therapy for cancer treatment: a perspective of the clinical trials conducted at Henry Ford Health

Novel Methods for Inducing Cardiac Tissue Regeneration Following Ischemic Injury

Contact Info

Product

Resources

About